Contact us to learn more about

our Premium Content: News alerts, weekly reports and conference planners

DRUG:

Kaitanni (cadonilimab)

Contact us to learn more about our Premium Content:

News alerts, weekly reports and conference planners

Company:

Akesobio

Drug class:

PD1 inhibitor, CTLA4 inhibitor

Related drugs:

‹

pembrolizumab (727)

nivolumab (607)

sintilimab (115)

toripalimab-tpzi (88)

camrelizumab (85)

tislelizumab-jsgr (84)

dostarlimab-gxly (43)

cemiplimab-rwlc (29)

zimberelimab (20)

pucotenlimab (12)

serplulimab (7)

retifanlimab-dlwr (6)

PF-06801591 (6)

JNJ-63723283 (5)

nivolumab/relatlimab-rmbw (4)

geptanolimab (3)

iparomlimab/tuvonralimab (3)

ivonescimab (3)

CMAB 819 (nivolumab biosimilar) (0)

EBV-specific anti-PD1 TCR-T cells (0)

enlonstobart (0)

prolgolimab (0)

NY-ESO-1 TCR-T cell therapy (0)

prolgolimab/nurulimab (0)

PD-1-KO-T cell injection (0)

PF-07209960 (0)

Undisclosed PD-1 inhibitor (0)

Undisclosed anti PD-1 mAb (0)

anti-PD-1 antibody (0)

ipilimumab (223)

tremelimumab (60)

ipilimumab biosimilar (CS1002) (2)

CTLA4 inhibitor (0)

IBI310 (ipilimumab biosimilar) (0)

PF-06753512 (0)

›

No biomarker	Cervical Cancer	No biomarker	Cervical Cancer	cadonilimab Sensitive: A1 - Approval cadonilimab Sensitive : A1	cadonilimab Sensitive: A1 - Approval cadonilimab Sensitive : A1
PD-L1 expression	Nasopharyngeal Carcinoma	PD-L1 expression	Nasopharyngeal Carcinoma	cadonilimab Sensitive: C2 – Inclusion Criteria cadonilimab Sensitive : C2	cadonilimab Sensitive: C2 – Inclusion Criteria cadonilimab Sensitive : C2
PD-L1 overexpression	Non Small Cell Lung Cancer	PD-L1 overexpression	Non Small Cell Lung Cancer	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3
HER-2 negative	Gastroesophageal Junction Adenocarcinoma	HER-2 negative	Gastroesophageal Junction Adenocarcinoma	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3
HER-2 negative	Gastric Cancer	HER-2 negative	Gastric Cancer	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3	cadonilimab + AK117 Sensitive: C3 – Early Trials cadonilimab + AK117 Sensitive : C3
PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	PD-L1 expression	Gastroesophageal Junction Adenocarcinoma	cadonilimab Sensitive: C3 – Early Trials cadonilimab Sensitive : C3	cadonilimab Sensitive: C3 – Early Trials cadonilimab Sensitive : C3
PD-L1 expression	Gastric Cancer	PD-L1 expression	Gastric Cancer	cadonilimab Sensitive: C3 – Early Trials cadonilimab Sensitive : C3	cadonilimab Sensitive: C3 – Early Trials cadonilimab Sensitive : C3
EGFR wild-type	Non Small Cell Lung Cancer	EGFR wild-type	Non Small Cell Lung Cancer	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3
ALK wild-type	Non Small Cell Lung Cancer	ALK wild-type	Non Small Cell Lung Cancer	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3
ROS1 wild-type	Non Small Cell Lung Cancer	ROS1 wild-type	Non Small Cell Lung Cancer	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3	anlotinib + cadonilimab Sensitive: C3 – Early Trials anlotinib + cadonilimab Sensitive : C3